Pluristem
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6201 15th Ave Ste 2, Brooklyn, New York,...Phone Number
+972 747108600Website
www.pluristem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Pluristem
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement forRead more
Pluristem Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pluristem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Pluristem is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Pluristem
Click to see if Pluristem had a recent Job posting/layoffs
Product Launch: Get notified when Pluristem launches new products
Earning: See what the market has to say on Pluristem recently announced quarterly report
Pluristem, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Pluristem has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pluristem has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Pluristem is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Pluristem is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Pluristem.
Pluristem financials insights
Gather financial insights about Pluristem, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Other Financing Round
$250K
Other Financing Round
$1.2M
2014
Grant
$4.2M
2015
Grant
$2.9M
Stock Offering
$17M
2016
Grant
$3.3M
Share Placement
$30M
2017
Multiple Rounds
$49M
2019
Stock Offering
$20M
2020
Debt
$56.2M
Share Placement
$15M
Pluristem Tech Stack
A closer look at the technologies used by Pluristem
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Partnership
Partnership, Research & Development, Product Management, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals, Manufacturing Operations
Left Company
Management Move
Sharon Shafran, Manager, Applications, has left the organization and now serves as the Head of Information Systems at Augury.
New Hire
Management Move
Pluristem News & Media
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harnessed for a range of fields beyond medicine, providing solutions for various areas of the life sciences. As of July 26, 2022, PluriPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA10 Best Biotech Penny Stocks To Buy Now
In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of the biotech sector, go directly to 5 Best Biotech Penny Stocks To Buy Now. Like all sectors of the economy right now, the biotech sector is going through a lot of pain. The […]Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Pluristem
Sign Up For FreeTo access detailed company insights
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PL... Read More
